CUREosity has successfully completed its first round of financing with selected angel investors. The lead investor Rhein Invest provided significant advice and support for the
Euro 1.1 million financing.
"The financing will enable CUREosity to develop its visionary rehabilitation method for people with neurological impairments as a marketable product.
It is our aim to ensure that a motivating and high-frequency therapy reaches patients promptly",
explains Thomas Saur, CEO of CUREosity GmbH.
About CUREosity GmbH
Currently more than 10 million (700 million worldwide) people with psychological and neurological impairments are affected in Germany (resulting from e.g. stroke, craniocerebral trauma, Parkinson's disease, multiple sclerosis, Alzheimer's disease or depression).
The consequences are the loss of independence, an increased need for personnel in
rehabilitation and rising costs of the social systems. This number will continue to rise due to the aging of society and progress in acute care.
Previous rehabilitation methods have not succeeded in countering this development. CUREosity wants to use intelligent concepts to help close the supply gap.
The founders of CUREosity (whose family members are affected) developed a completely new, worldwide unique rehabilitation and training method based on VR technology.
The first prototype of a therapy system for cognitive and motor rehabilitation shows high acceptance and impressive results in the first clinical practice.
The founders and their accompanying team of doctors rely on current neuroscientific findings. Efficient methods are used to utilize the neuroplasticity of the brain for the production of lost abilities. The aim is to return more affected people to a self-determined life with as little help from others as possible. New possibilities of individual and group therapy are opening up for therapists.
Managing directors: Stefan Arand, Thomas Saur, Marco Faulhammer
About RHEIN INVEST GmbH
Rhein Invest, based in Düsseldorf, was founded in 2018 to provide start-up companies with seed capacity. The company pursues a consulting-intensive approach, which enables the respective start-ups to be supported in a variety of ways during the start-up and growth phases.
Managing Directors: Dr. Bernhard Düttmann, Rolf Fellmann, Ralph Giebel
and Andreas G. Zetzsche